[Skip to Content]
[Skip to Content Landing]
Article
February 24, 1989

Haemophilus b Polysaccharide Vaccine

Author Affiliations

Centers for Disease Control Atlanta New York State Department of Health Albany
New York State Department of Health Albany

Centers for Disease Control Atlanta New York State Department of Health Albany
New York State Department of Health Albany

JAMA. 1989;261(8):1152. doi:10.1001/jama.1989.03420080066028
Abstract

To the Editor. —  The Sept 9 issue of The Journal highlighted the continuing controversy regarding the efficacy of the Haemophilus b polysaccharide vaccine. While the majority of studies cite a vaccine efficacy of 44% to 90%,1-3 the case-control study from Minnesota raised questions not only regarding efficacy but also about possible negative effects of vaccination.4 During 1986, Alexander et al5 published population-based data from Jefferson County, Alabama, that showed a significant reduction in the number of cases of invasive Haemophilus influenzae type b (Hib) disease during 1986 among children aged 24 to 48 months, suggesting that the vaccine had lowered the incidence of disease within that age group.We reviewed age-specific hospitalization information for H influenzae meningitis using federally standardized computer data on all hospital discharges (about 3 million per year) from all general hospitals (N = 295) in New York State (population, 17.76 million) for 1980

×